Exagen (XGN) Files 8-K, Furnishes Q2 2025 Earnings Press Release

Exagen Inc. (Nasdaq: XGN) filed a Form 8-K dated July 29, 2025.

Rhea-AI Filing Summary

Exagen Inc. (Nasdaq: XGN) filed a Form 8-K dated July 29, 2025. The filing is limited to the disclosure that, on the same date, the company released its unaudited financial results for the three- and six-month periods ended June 30, 2025.

Item 2.02 – Results of Operations and Financial Condition: The related earnings press release is furnished as Exhibit 99.1. Because the information is furnished—not filed—it is expressly excluded from Section 18 liability and is not automatically incorporated by reference into other SEC filings.

Item 9.01 – Exhibits: 99.1 (Press Release dated July 29, 2025) and 104 (Cover Page iXBRL).

No additional material events, financial metrics, or strategic updates are included in this report.

Insights

Financial Analyst

TL;DR: Routine 8-K merely furnishes Q2 2025 earnings press release; no figures disclosed, so market impact is likely neutral.

The filing meets compliance requirements by promptly submitting the earnings release under Item 2.02. However, without embedded revenue, EPS, or guidance data, investors must review Exhibit 99.1 for substantive insight. The company also clarifies the information is furnished, limiting legal exposure. Overall, this is a standard procedural disclosure with no direct valuation impact until the actual numbers are reviewed.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Exagen Inc. file on July 29 2025?

Form 8-K announcing that Q2 2025 financial results were released and furnished as Exhibit 99.1.

Which items are covered in the XGN Form 8-K?

Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).

Does the 8-K include Exagen’s Q2 2025 revenue and EPS figures?

No. The filing only references a press release; actual numbers are in Exhibit 99.1, not in the 8-K text.

What exhibits accompany the filing?

Exhibit 99.1 (Press Release dated July 29 2025) and Exhibit 104 (Cover Page Inline XBRL).

Is the furnished information considered "filed" for liability purposes?

No. Exagen states the data is furnished, so it is not subject to Section 18 liabilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2025 - 08:02 AM Learn about SEC filing dates

0001274737FALSE00012747372025-07-292025-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2025

EXAGEN INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39049

20-0434866

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1261 Liberty Way

Vista, CA 92081

(Address of principal executive offices) (Zip Code)

(760) 560-1501

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

XGN

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 29, 2025, the Company reported its financial results for the three and six months ended June 30, 2025. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release dated July 29, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXAGEN INC.

Date: July 29, 2025

By:

/s/ Jeffrey G. Black

Jeffrey G. Black

Chief Financial Officer